Notice of Allowance from Israel Patent Office
Filed with ASX · · 2 pages · English
Cynata Therapeutics Limited on 6ix
Story so far
Earlier from Cynata Therapeutics
- December 2019 Quarterly Report
- Cynata Therapeutics: UK Regulatory Authority Approves Cynata’s Phase 2 Clinical Trial in Critical Limb Ischaemia
- Cynata Receives UK Regulatory Approval for CLI Trial
- Cynata Receives $1.892m R&D Tax Incentive Refund
- Cymerus MSCs Effective in Preclinical Model of Sepsis
Later from Cynata Therapeutics
- Market Update & Additional A$618k R&D Tax Refund
- Cynata provides guidance on planned clinical trials
- Cynata MSCs beneficial in preclinical ARDS study
- Cynata announces $5.55m capital raising
- Share Purchase Plan Booklet
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics